Geospatial study identifies hotspots in deaths from HIV/AIDS and Hepatitis C in Massachusetts

December 11, 2014

BOSTON (December 11, 2014) -- A new study from epidemiologists at Tufts University School of Medicine helps to identify communities with the greatest public health need in Massachusetts for resources relating to HIV/AIDS and hepatitis C. The study, published today in PLOS ONE, used geospatial techniques to identify hotspots for deaths related to HIV/AIDS and hepatitis C. The findings show large disparities in death rates exist across race and ethnicity in Massachusetts.

The HIV/AIDS and hepatitis C epidemics are challenging public health officials and clinicians in the United States. While HIV/AIDS mortality rates have decreased, hepatitis C infection rates have increased at a steep rate in younger populations. Co-infection is common among drug users. Public health officials are also increasingly concerned about long-standing and initially silent hepatitis C infections in baby boomers.

Studies of mortality frequently use only one cause of death, but these studies often miss the underlying cause of death. To get a fuller picture, the research team looked at the contributing or underlying causes of death, related to HIV/AIDS or hepatitis C, as documented on death certificates from 2002 to 2011 in the Commonwealth of Massachusetts.

Hispanic and black populations die at rates up to five times greater than white and Asian populations from HIV/AIDS or hepatitis C, particularly those aged 45-65. Springfield, Worcester, South Boston, the Merrimack Valley, and New Bedford had the highest rates of death from HIV/AIDS or hepatitis C and are identified as the communities in greatest need of resources for reducing disparities.

"Many neighborhoods and towns are affected by these intertwined epidemics, but some neighborhoods and municipalities have been hit particularly hard. While these specific communities are hardest hit now, hepatitis C has been increasing in young, nonurban, white, populations so preventing transmission - particularly because it often takes about 20 to 30 years for symptoms to show up - is paramount," said senior author Tom Stopka, Ph.D., assistant professor of public health and community medicine at Tufts University School of Medicine.

"Comprehensive prevention should include health education, enhanced counseling and testing, linkage to care, and increased access to sterile syringes through syringe exchange programs and pharmacies. Expanded treatment is also essential, for both HIV and hepatitis C, to decrease transmission risks in local communities," he continued.

The research team looked at all death certificates in Massachusetts from 2002 to 2011 that had HIV/AIDS or hepatitis C as an underlying or contributing cause of death. Using population estimates, they calculated mortality rates in each census tract across the state by race and age.

The researchers conducted geospatial and temporal hotspot analyses to see what areas had clusters of higher mortality rates for HIV/AIDS and hepatitis C compared to the rest of the state and portrayed the results in maps.

Detailed findings: "I conducted this study to better highlight the enormous, yet preventable, disparities that exist in infectious disease mortality, especially in the case of AIDS and hepatitis C. By analyzing who is dying from these conditions, and where, we can figure out the best ways to organize a targeted response to improve health equity," said first author, David Meyers, M.P.H. Meyers conducted the study as part of his MPH degree program at Tufts University School of Medicine. He is currently an analyst at the Harvard School of Public Health.

While anyone can get hepatitis C, more than 75% of adults infected are baby boomers, perhaps as a result of receiving contaminated blood before the blood supply was screened beginning in 1992. People can live with hepatitis C for decades without symptoms. Chronic hepatitis C can lead to serious health problems including liver damage, but new, highly effective medications are available.

No external funding contributed to this research.
-end-
Citation: Meyers DJ, Hood ME, Stopka TJ (2014). HIV and Hepatitis C Mortality in Massachusetts, 2002-2011: Spatial Cluster and Trend Analysis of HIV and HCV Using Multiple Cause of Death. PLoS ONE 9(12): e114822. doi:10.1371/journal.pone.0114822 http://dx.plos.org/10.1371/journal.pone.0114822

About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical and population health education and advanced research. Tufts University School of Medicine emphasizes rigorous fundamentals in a dynamic learning environment to educate physicians, scientists, and public health professionals to become leaders in their fields. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, the biomedical sciences, and public health, as well as for innovative research at the cellular, molecular, and population health level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its effect on the advancement of medical and prevention science.

Tufts University, Health Sciences Campus

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.